Rhythm Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RYTM and other ETFs, options, and stocks.

About RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. 

CEO
David P. Meeker
CEODavid P. Meeker
Employees
414
Employees414
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2008
Founded2008
Employees
414
Employees414

RYTM Key Statistics

Market cap
6.18B
Market cap6.18B
Price-Earnings ratio
-28.11
Price-Earnings ratio-28.11
Dividend yield
Dividend yield
Average volume
873.79K
Average volume873.79K
High today
$91.28
High today$91.28
Low today
$72.45
Low today$72.45
Open price
$88.55
Open price$88.55
Volume
859.35K
Volume859.35K
52 Week high
$122.20
52 Week high$122.20
52 Week low
$45.91
52 Week low$45.91

Stock Snapshot

The current Rhythm Pharmaceuticals(RYTM) stock price is $86.00, with a market capitalization of 6.18B. The stock trades at a price-to-earnings (P/E) ratio of -28.11.

During the trading session on 2026-03-16, Rhythm Pharmaceuticals(RYTM) shares reached a daily high of $91.28 and a low of $72.45. At a current price of $86.00, the stock is +18.7% higher than the low and still -5.8% under the high.

Trading activity shows a volume of 859.35K, compared to an average daily volume of 873.79K.

The stock's 52-week range extends from a low of $45.91 to a high of $122.20.

The stock's 52-week range extends from a low of $45.91 to a high of $122.20.

RYTM News

TipRanks 53m
Rhythm Pharmaceuticals Reports Mixed Phase 3 EMANATE Results

Rhythm Pharmaceuticals ( (RYTM) ) has provided an update. On March 16, 2026, Rhythm Pharmaceuticals reported topline data from EMANATE, a global Phase 3 trial...

Analyst ratings

94%

of 16 ratings
Buy
93.8%
Hold
6.3%
Sell
0%

People also own

Based on the portfolios of people who own RYTM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.